On Tuesday, Lucid Diagnostics Inc (NASDAQ: LUCD) was 6.67% up from the session before settling in for the closing price of $1.20. A 52-week range for LUCD has been $0.63 – $1.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 119.69% over the past five years. When this article was written, the company’s average yearly earnings per share was at 35.70%. With a float of $39.91 million, this company’s outstanding shares have now reached $63.07 million.
Let’s look at the performance matrix of the company that is accounted for 72 employees. In terms of profitability, gross margin is -80.14%, operating margin of -1059.66%, and the pretax margin is -1047.61%.
Lucid Diagnostics Inc (LUCD) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lucid Diagnostics Inc stocks. The insider ownership of Lucid Diagnostics Inc is 62.03%, while institutional ownership is 4.29%.
Lucid Diagnostics Inc (LUCD) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 35.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.08% during the next five years compared to -54.43% drop over the previous five years of trading.
Lucid Diagnostics Inc (NASDAQ: LUCD) Trading Performance Indicators
You can see what Lucid Diagnostics Inc (LUCD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Lucid Diagnostics Inc (LUCD)
Lucid Diagnostics Inc (NASDAQ: LUCD) saw its 5-day average volume 0.77 million, a negative change from its year-to-date volume of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 23.44%. Additionally, its Average True Range was 0.14.
During the past 100 days, Lucid Diagnostics Inc’s (LUCD) raw stochastic average was set at 50.47%, which indicates a significant increase from 28.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 141.32% in the past 14 days, which was higher than the 86.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4029, while its 200-day Moving Average is $0.9936. Nevertheless, the first resistance level for the watch stands at $1.3133 in the near term. At $1.3467, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4033. If the price goes on to break the first support level at $1.2233, it is likely to go to the next support level at $1.1667. The third support level lies at $1.1333 if the price breaches the second support level.
Lucid Diagnostics Inc (NASDAQ: LUCD) Key Stats
There are 90,754K outstanding shares of the company, which has a market capitalization of 134.83 million. As of now, sales total 4,350 K while income totals -45,530 K. Its latest quarter income was 1,200 K while its last quarter net income were -11,540 K.
